Remember me
Zhu JR, Gao RL, Zhao SP, et al. 2016 Chinese guidelines for the management of dyslipidemia in adults. J Geriatr Cardiol 2018; 15: 1−29.
[3]Li JJ, Zhao SP, Zhao D, et al. Chinese guidelines for lipid management (2023). Front Pharmacol 2023: online.
[4] Li S, Liu HH, Guo YL, et al. Improvement of evaluation in Chinese patients with atherosclerotic cardiovascular disease using the very-high-risk refinement: A population-based study. Lancet Reg Health West Pac 2021; 17: 100286. doi: 10.1016/j.lanwpc.2021.100286 [5]Grundy SM, Stone NJ, Bailey AL, et al. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2018; 139: e1082−e1143.
[6]Lu Z, Kou W, Du B, et al. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol 2008, 101: 1689–1693.
[7] Li J-J, Lu Z-L, Kou WR, et al. Impact of Xuezhikang on coronary events in hypertensive patients with previous myocardial infarction from the China Coronary Secondary Prevention Study (CCSPS). Ann Med 2010; 42: 231−240. doi: 10.3109/07853891003652534 [8]Center for Disease Control and Prevention of National Health Commission of the People’s Republic of China (2020). Report on nutrition and chronic diseases of Chinese residents 2020 (in Chinese). Beijing: People’s Medical Press.
[9] Cao YX, Sun D, Liu HH, et al. A novel modified system of simplified Chinese criteria for familial hypercholesterolemia (SCCFH). Mol Diagn Ther 2019; 23: 547−553. doi: 10.1007/s40291-019-00405-1 [10] Cao YX, Wu NQ, Sun D, et al. Application of expanded genetic analysis in the diagnosis of familial hypercholesterolemia in patients with very early-onset coronary artery disease. J Transl Med 2018; 16: 345. doi: 10.1186/s12967-018-1737-7
Comments (0)